Efficacy and safety of new generic of direct acting antivirals in the treatment of chronic hepatitis C

The management of chronic hepatitis C infection is currently in change. IFN based treatments were the standard therapy, against HCV infection waiting for pending authorization to place the direct acting antivirals on the market. These new direct acting antivirals generic conferred good effectiveness and safety for infected patients. The aim of this study was to characterize the treatment response and tolerance of new generics of DAAs in patients infected with hepatitis C virus. The study was conducted at the gastroenterology I department of the military hospital Mohamed V in Rabat since December 2015. We include all patients infected with HCV: naïf relapsing or non-responsive profiles, all genotypes combined, cirrhotic or not. They all received treatment with the new Moroccan generic of direct acting antivirals. Virological response as well as clinical and biochemical tolerances were achieved. 77 patients with viral hepatitis C were included in the study. The average age of the patients was 61 ± 11 years old. A slight predominance of women noted in 52.8% of cases. Genotype 1 was predominant in 74% of cases. Half of our patients were cirrhotic. The sustained virogical response SVR was of the order of 96.2%. The treatment generally well tolerated in all our patients. The generic of direct acting antivirals promises treatments with shorter treatment times, much higher cure rates, and fewer side effects. Viral eradication leads stabilization or regression of fibrosis.